


Clinical impact of serum soluble SLAMF7 in multiple myeloma

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Results of univariate and multivariate analyses

Variable		Univariate analysis			Multivariate analysis		
		HR	95% CI	P value	HR	95% CI	P value
Serum sSLAMF7 (Positive vs. Negative)		2.28	1.04-5.02	0.035	1.57	0.704-3.63	0.262
R-ISS	I vs. II	3.86	0.510-29.3	0.164	3.32	0.428-25.7	0.251
	I vs. III	9.42	1.17-75.8	0.021	7.72	0.926-64.4	0.059

HR, hazard ratio; 95% CI, 95% confidence interval.



Supplementary Figure 1: Relationship between sSLAMF7 and plasma cells from MM patients. (A) Correlation of serum sSLAMF7 with the percentage of bone marrow (BM) plasma cells from MM patients. (B) Comparison of the percentage of BM plasma cells between serum sSLAMF7-negative and -positive MM patients. (C) Correlation of serum sSLAMF7 with SLAMF7 mRNA levels in BM plasma cells. CD138⁺ plasma cells were isolated from BM mononuclear cells of MM patients using a CD138⁺ plasma cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). After total RNA extraction, cDNA from total RNA was synthesized, and then quantification of mRNA using real-time PCR was performed. (D) Comparison of SLAMF7 mRNA levels of BM plasma cells between serum sSLAMF7-negative and -positive MM patients.